Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Conatus Pharmaceuticals has reported positive preclinical results on its lead compound CTS-1027 in multiple models of hepatitis, an inflammatory liver disease.
Subscribe to our email newsletter
CTS-1027 significantly reduced liver damage following oral administration in four different preclinical models of liver injury. CTS-1027 markedly reduced aminotransferase (ALT) activity and improved survival and liver histology in the TNFalpha/Gln model. CTS-1027 was equally effective dosed at the same time as the insult or post-insult in the LPS/Gln model. CTS-1027 significantly reduced ALT activity in the Fas and Con A models. Dosing was well below or equivalent to exposure levels previously tolerated in human clinical studies.
CTS-1027 is an oral, small molecule, matrix metalloproteinase inhibitor under development for chronic use to protect the liver from damage due to a variety of insults including virus infection, obesity, alcohol use and autoimmune diseases.
Alfred Spada, senior vice president for R&D, said: “CTS-1027 represents a potential new and exciting approach to treat patients infected with hepatitis C virus (HCV), and in the treatment of other liver diseases. Our initial goal for the development of CTS-1027 is to establish safety and efficacy in patients infected with HCV who have failed or can not tolerate standard of care. We plan to initiate a Phase II clinical trial within the next few months.”